We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
Read MoreHide Full Article
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS - Free Report) and Exact Sciences (EXAS - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Keros Therapeutics, Inc. and Exact Sciences are sporting Zacks Ranks of #1 (Strong Buy) and #2 (Buy), respectively, right now. This means that KROS's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is only part of the picture for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
KROS currently has a forward P/E ratio of 70.11, while EXAS has a forward P/E of 303.06. We also note that KROS has a PEG ratio of 2.62. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. EXAS currently has a PEG ratio of 10.35.
Another notable valuation metric for KROS is its P/B ratio of 0.81. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, EXAS has a P/B of 3.82.
These metrics, and several others, help KROS earn a Value grade of B, while EXAS has been given a Value grade of C.
KROS sticks out from EXAS in both our Zacks Rank and Style Scores models, so value investors will likely feel that KROS is the better option right now.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS - Free Report) and Exact Sciences (EXAS - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Keros Therapeutics, Inc. and Exact Sciences are sporting Zacks Ranks of #1 (Strong Buy) and #2 (Buy), respectively, right now. This means that KROS's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is only part of the picture for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
KROS currently has a forward P/E ratio of 70.11, while EXAS has a forward P/E of 303.06. We also note that KROS has a PEG ratio of 2.62. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. EXAS currently has a PEG ratio of 10.35.
Another notable valuation metric for KROS is its P/B ratio of 0.81. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, EXAS has a P/B of 3.82.
These metrics, and several others, help KROS earn a Value grade of B, while EXAS has been given a Value grade of C.
KROS sticks out from EXAS in both our Zacks Rank and Style Scores models, so value investors will likely feel that KROS is the better option right now.